Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Aptevo Therapeutics Q2 EPS $(8.40) Beats $(83.20) Estimate

Author: Benzinga Newsdesk | August 11, 2025 07:10am

Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(8.40) per share which beat the analyst consensus estimate of $(83.20) by 89.9 percent. This is a 99.32 percent increase over losses of $(1.24 thousand) per share from the same period last year.

Posted In: APVO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist